Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer

PURPOSE: The objectives of this analysis were to characterize the population pharmacokinetics (PK) of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) sourced from the European Union (bevacizumab-EU) in patients with advanced non-squamous non-small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Cheryl S. W., Sweeney, Kevin, Cronenberger, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036079/
https://www.ncbi.nlm.nih.gov/pubmed/31768697
http://dx.doi.org/10.1007/s00280-019-03946-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036079/
https://www.ncbi.nlm.nih.gov/pubmed/31768697
http://dx.doi.org/10.1007/s00280-019-03946-8

Ejemplares similares